Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM). He summarizes the study design, patient population, efficacy outcomes, and safety profile, highlighting rapid, deep, and durable responses with a manageable incidence of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. During the discussion, Dr. Mansi Shah, Dr. Cesar Rodriguez, and Dr. Ridhi Gupta examine how linvoseltamab compares with other BCMA bispecific antibodies, emphasizing its predictable cytokine release syndrome profile, response-adapted dosing schedule, and potential advantages for outpatient administration. The panel also discusses practical considerations for patient selection, infection prevention strategies, use of intravenous immunoglobulin and antimicrobial prophylaxis, and factors influencing outpatient versus inpatient administration. Faculty conclude by considering how linvoseltamab may be incorporated into evolving treatment algorithms for relapsed/refractory multiple myeloma as BCMA-directed therapies continue to move into earlier lines of therapy.